Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1995 Nov 18;311(7016):1340–1343. doi: 10.1136/bmj.311.7016.1340

Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer.

C Parkes 1, N J Wald 1, P Murphy 1, L George 1, H C Watt 1, R Kirby 1, P Knekt 1, K J Helzlsouer 1, J Tuomilehto 1
PMCID: PMC2551245  PMID: 7496284

Abstract

OBJECTIVE--To evaluate measurement of serum prostate specific antigen as a potential screening test for future clinical prostate cancer among healthy men. DESIGN--Nested case-control study with stored serum samples collected from 49,261 men with follow up using national death and cancer registration systems. SUBJECTS--265 asymptomatic men who subsequently developed clinical prostate cancer and 1055 controls matched for age, study centre, and duration of storage of samples. MAIN OUTCOME MEASURES--Distribution of concentrations of the antigen in men who developed prostate cancer and in controls. RESULTS--Prostate specific antigen concentrations were significantly higher in men who subsequently developed prostate cancer than in controls. In the first three years after blood collection the median concentration was 23 times greater in cases than in controls of the same age at the same centre (that is, 23 multiples of the median). A smaller difference persisted thereafter; 4.0 multiples of the median 3-6 years after blood collection, 3.6 6-10 years, and 1.8 after 10 years. In the first three years the proportion of men who developed prostate cancer and had raised levels of the antigen (> or = 12 multiples of the median) (detection rate or sensitivity) was 81% (95% confidence interval 54% to 96%). The proportion of men who did not develop prostate cancer but had levels this high (false positive rate) was only 0.5%. CONCLUSION--Prostate specific antigen measurement is a highly discriminatory screening test for prostate cancer among healthy men. In the general population, 60-74 year old men who had > or = 12 times the normal median level would have about a 50% chance of developing clinical prostate cancer in the next three years. Measurement of this antigen is a good enough screening test to justify a randomised controlled trial to determine any reduction in mortality from prostate cancer.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Breslow N., Chan C. W., Dhom G., Drury R. A., Franks L. M., Gellei B., Lee Y. S., Lundberg S., Sparke B., Sternby N. H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977 Nov 15;20(5):680–688. doi: 10.1002/ijc.2910200506. [DOI] [PubMed] [Google Scholar]
  2. Carter H. B., Pearson J. D., Metter E. J., Brant L. J., Chan D. W., Andres R., Fozard J. L., Walsh P. C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22;267(16):2215–2220. [PMC free article] [PubMed] [Google Scholar]
  3. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  4. Chodak G. W., Thisted R. A., Gerber G. S., Johansson J. E., Adolfsson J., Jones G. W., Chisholm G. D., Moskovitz B., Livne P. M., Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994 Jan 27;330(4):242–248. doi: 10.1056/NEJM199401273300403. [DOI] [PubMed] [Google Scholar]
  5. FRANKS L. M. Latent carcinoma of the prostate. J Pathol Bacteriol. 1954 Oct;68(2):603–616. doi: 10.1002/path.1700680233. [DOI] [PubMed] [Google Scholar]
  6. Gann P. H., Hennekens C. H., Stampfer M. J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995 Jan 25;273(4):289–294. [PubMed] [Google Scholar]
  7. Helzlsouer K. J., Comstock G. W., Morris J. S. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res. 1989 Nov 1;49(21):6144–6148. [PubMed] [Google Scholar]
  8. Helzlsouer K. J., Newby J., Comstock G. W. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):537–540. [PubMed] [Google Scholar]
  9. Johansson J. E., Adami H. O., Andersson S. O., Bergström R., Holmberg L., Krusemo U. B. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992 Apr 22;267(16):2191–2196. [PubMed] [Google Scholar]
  10. Kabalin J. N., McNeal J. E., Price H. M., Freiha F. S., Stamey T. A. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol. 1989 May;141(5):1091–1094. doi: 10.1016/s0022-5347(17)41178-5. [DOI] [PubMed] [Google Scholar]
  11. Killian C. S., Chu T. M. Prostate-specific antigen: questions often asked. Cancer Invest. 1990;8(1):27–37. doi: 10.3109/07357909009017544. [DOI] [PubMed] [Google Scholar]
  12. Knekt P., Aromaa A., Maatela J., Alfthan G., Aaran R. K., Teppo L., Hakama M. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. Int J Cancer. 1988 Dec 15;42(6):846–850. doi: 10.1002/ijc.2910420609. [DOI] [PubMed] [Google Scholar]
  13. Oesterling J. E., Jacobsen S. J., Chute C. G., Guess H. A., Girman C. J., Panser L. A., Lieber M. M. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993 Aug 18;270(7):860–864. [PubMed] [Google Scholar]
  14. Stamey T. A., Kabalin J. N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol. 1989 May;141(5):1070–1075. doi: 10.1016/s0022-5347(17)41174-8. [DOI] [PubMed] [Google Scholar]
  15. Stenman U. H., Hakama M., Knekt P., Aromaa A., Teppo L., Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994 Dec 10;344(8937):1594–1598. doi: 10.1016/s0140-6736(94)90405-7. [DOI] [PubMed] [Google Scholar]
  16. Wald N. J., Thompson S. G., Densem J. W., Boreham J., Bailey A. Serum vitamin E and subsequent risk of cancer. Br J Cancer. 1987 Jul;56(1):69–72. doi: 10.1038/bjc.1987.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Whittemore A. S., Lele C., Friedman G. D., Stamey T., Vogelman J. H., Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst. 1995 Mar 1;87(5):354–360. doi: 10.1093/jnci/87.5.354. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES